Isoprenaline Hydrochloride Macure (Isoprenaline Hydrochloride)

The drug binds to both beta‑1 and beta‑2 adrenergic receptors, activating adenylate cyclase and increasing cyclic AMP levels. This cascade enhances cardiac pacemaker activity and contractility while also causing bronchodilation through smooth‑muscle relaxation.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, and response. Dosing is individualized and should follow local clinical guidelines and the prescriber’s judgment.

Safety data are limited; the product is classified as pregnancy category unknown. It should only be used during pregnancy or lactation if the potential therapeutic benefit justifies any potential risk to the fetus or infant, and after careful risk‑benefit assessment by the healthcare provider.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and assists with import documentation.

Isoprenaline is a non‑selective beta‑adrenergic agonist, providing both cardiac (beta‑1) and bronchodilator (beta‑2) effects. Compared with selective beta‑2 agents such as albuterol, it has a stronger impact on heart rate and contractility, making it suitable for combined cardiac and respiratory emergencies.

Store the injectable solution at ambient temperature, below 25 °C, in its original packaging. Protect it from light, moisture, and extreme temperatures. Do not freeze. Inspect the vial for particulate matter before use.

The drug is given intravenously, typically as a controlled infusion. Administration should be performed by qualified healthcare professionals in a setting where cardiac monitoring is available, allowing rapid adjustment of the infusion rate as needed.

Serious risks include life‑threatening arrhythmias, myocardial ischemia, severe hypotension, pulmonary edema, and anaphylactic reactions. Immediate medical attention is required if any of these events occur during or after infusion.

Patients with uncontrolled tachyarrhythmias, severe hypertension, recent myocardial infarction, or known hypersensitivity to the product should not receive Isoprenaline. Contraindications must be evaluated by the treating physician before initiation.